BEAM:NASDAQ
Beam Therapeutics Inc
$24.28
arrow_downward
-0.37%(-0.090) 1D
Sep 11, 2:01:25 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEAM...
Open
$24.64
High
$24.76
Low
$24.10
Mkt. cap
2.51B
Avg. vol.
1.76M
Volume
540.72K
52-wk high
$38.26
52-wk low
$20.23
EPS
-$0.81
Beta
2.22
Shares outstanding
103.29M
No. of employees
540
Open
$24.64
High
$24.76
Low
$24.10
Mkt. cap
2.51B
Avg. vol.
1.76M
Volume
540.72K
52-wk high
$38.26
52-wk low
$20.23
EPS
-$0.81
Beta
2.22
Shares outstanding
103.29M
No. of employees
540
News stories
From web sources and news partners
Simply Wall Street
·
1 day ago
Clinical Trial Progress Might Change The Case For Investing In Beam Therapeutics Stock (BEAM)
Investing.com
·
1 day ago
Beam Therapeutics at Citi summit: platform gains momentum across pipeline
Investing.com
·
2 days ago
Beam Therapeutics at Wells Fargo conference: base editing gains ground
Yahoo Finance
·
3 days ago
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
Profile
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia
About Beam Therapeutics Inc